5.55
+0.06(+1.09%)
Currency In USD
| Previous Close | 5.49 |
| Open | 5.6 |
| Day High | 5.91 |
| Day Low | 5.48 |
| 52-Week High | 26.05 |
| 52-Week Low | 3.13 |
| Volume | 487,575 |
| Average Volume | 234,054 |
| Market Cap | 83.37M |
| PE | -1.05 |
| EPS | -5.27 |
| Moving Average 50 Days | 5.13 |
| Moving Average 200 Days | 11.75 |
| Change | 0.06 |
If you invested $1000 in Jasper Therapeutics, Inc. (JSPR) since IPO date, it would be worth $56.52 as of June 30, 2025 at a share price of $5.55. Whereas If you bought $1000 worth of Jasper Therapeutics, Inc. (JSPR) shares 3 years ago, it would be worth $287.56 as of June 30, 2025 at a share price of $5.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
GlobeNewswire Inc.
Jun 14, 2025 2:00 PM GMT
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participa
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
GlobeNewswire Inc.
Jun 03, 2025 12:00 PM GMT
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mas
Jasper Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
May 14, 2025 8:30 PM GMT
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driv